Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. (Q33785308)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205109%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

review article

1 reference

title

Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205109%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205109%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Kamlesh Khunti

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205109%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

R Kela

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205109%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205109%20AND%20SRC:MED&resulttype=core&format=json

Diabetes, Obesity and Metabolism

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205109%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205109%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205109%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

207-220

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205109%20AND%20SRC:MED&resulttype=core&format=json

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

beta-cell failure in diabetes and preservation by clinical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Effect of renal impairment on the pharmacokinetics of exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Point: visceral adiposity is causally related to insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

Secretion of the Incretin Hormones Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide Correlates with Insulin Secretion in Normal Man Throughout the Day

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01330.X

10.1111/J.1463-1326.2010.01330.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21205109%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference